Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.
Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.